Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study

Publisher： Karger

E-ISSN： 1661-3805|2|4|227-233

ISSN： 1661-3791

Source： Breast Care, Vol.2, Iss.4, 2007-08, pp. : 227-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite

Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 168-171

Karger

Access to resources Recommend Favorite

Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

By  

Breast Care, Vol. 11, Iss. 2, 2016-02 ,pp. : 133-138

Karger

Access to resources Recommend Favorite

Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 406-410

Karger

Access to resources Recommend Favorite

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 184-191

Karger

Access to resources Recommend Favorite